New drug aims to calm immune overreaction in pneumonia patients with sepsis
NCT ID NCT06669403
First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug, OPT101, in 26 adults hospitalized with community-acquired pneumonia and sepsis. The goal is to check if the drug is safe and how the body processes it. Participants receive either OPT101 or a placebo for up to 4 days, and researchers monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Denver Health and Hospital Authority
Denver, Colorado, 80204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.